Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BridgeBio Pharma, Inc.BBIO · Entity 3360 | CFO and Treasurer | February 25, 2025 | February 27, 2025 |
| Faeth Therapeutics, Inc.FTH · Entity 5029 | Chief Financial Officer | June 29, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BridgeBio Pharma, Inc.
Report date February 25, 2025 · Filed February 27, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,464 |
Ending reported balance
After 2025-02-25 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-02-25 · Exercise / conversion · Acquired 8,500 · Balance 110,964 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. Row 2 · 2025-02-25 · Sale · Disposed 8,400 · Balance 102,564 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F2: Represents the weighted average sale price of the shares sold from $32.63 to $33.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Row 3 · 2025-02-25 · Sale · Disposed 100 · Balance 102,464 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.00 · Expires 2029-06-26 | Direct | 440,170 |
Reported balance
After 2025-02-25 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-25 · Exercise / conversion · Disposed 8,500 · Balance 440,170 F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024. F3: The shares subject to this option vested in 48 equal monthly installments from June 26, 2019 to June 26, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 22, 2024.
F2: Represents the weighted average sale price of the shares sold from $32.63 to $33.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
F3: The shares subject to this option vested in 48 equal monthly installments from June 26, 2019 to June 26, 2023.
Faeth Therapeutics, Inc.
Report date June 29, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 46,688 |
Last balance in matching sequence
After 2026-07-01 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
6 source rowsRow 1 · 2026-06-29 · Purchase · Acquired 831 · Balance 33,885 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.20 to $23.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 2 · 2026-06-30 · Purchase · Acquired 1,910 · Balance 35,795 F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.45 to $23.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 3 · 2026-06-30 · Purchase · Acquired 1,638 · Balance 37,433 F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.50 to $24.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 4 · 2026-06-30 · Purchase · Acquired 4,255 · Balance 41,688 F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.59 to $25.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 5 · 2026-07-01 · Purchase · Acquired 4,400 · Balance 46,088 F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.14 to $23.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. Row 6 · 2026-07-01 · Purchase · Acquired 600 · Balance 46,688 F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.14 to $24.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.20 to $23.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2: These shares are held directly by the Brian Stephenson Revocable Trust (the "Trust"), of which the Reporting Person is the sole trustee and has sole voting and investment power over all securities owned by the Trust. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.45 to $23.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F4: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.50 to $24.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F5: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.59 to $25.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F6: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $23.14 to $23.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F7: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.14 to $24.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 16, 2024 Filed Aug 20, 2024 22:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 13,077 | $24.40 | $319,078.80 |
DisclosureSEC source: 0000950170-24-099269 · ownership.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,347 F3 · shares: Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 25,797 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 22:27 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 25,797 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-099269 · ownership.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 155 shares of the Issuer's Common Stock acquired by the Reporting Person on August 15, 2024 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:09 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 6,704 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-061638 · ownership.xml · derivative · entry 7 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,574 Underlying: Common Stock · 6,704 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F7 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:09 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 17,368 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-061638 · ownership.xml · derivative · entry 6 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,052 Underlying: Common Stock · 17,368 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F6 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:09 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-061638 · ownership.xml · derivative · entry 5 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,679 Underlying: Common Stock · 947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vested with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F5 · derivative.expiration_date: The RSUs vested with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:09 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-061638 · ownership.xml · derivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,335 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F4 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:09 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-061638 · ownership.xml · derivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on August 16, 2020. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F3 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on August 16, 2020. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:09 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 13,943 | $31.04 | $432,790.72 |
DisclosureSEC source: 0000950170-24-061638 · ownership.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,472 F2 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 27,507 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| May 16, 2024 Filed May 17, 2024 20:09 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 27,507 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-061638 · ownership.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 20:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantRestricted Stock Units · Derivative | 107,278 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-031431 · ownership.xml · derivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,278 Underlying: Common Stock · 107,278 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2024, and thereafter, 1/16th of the underlying shares will vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F3 · derivative.expiration_date: The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2024, and thereafter, 1/16th of the underlying shares will vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 20:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | GrantStock Option (right to buy) · Derivative | 15,442 | $0.00 Strike: $28.70 | $0.00 |
DisclosureSEC source: 0000950170-24-031431 · ownership.xml · derivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,442 Underlying: Common Stock · 15,442 shares Expires 2034-03-11 F1 · derivative.exercise_date: 1/16th of the shares subject to this option vest and become excercsiable on May 16, 2024, and thereafter, 1/16th of the shares subject to this option will vest and become exercisable on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:04 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 17,369 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-017895 · ownership.xml · derivative · entry 7 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,420 Underlying: Common Stock · 17,369 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F8 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:04 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 946 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-017895 · ownership.xml · derivative · entry 6 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,626 Underlying: Common Stock · 946 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The RSUs vested with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F7 · derivative.expiration_date: The RSUs vested with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:04 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 24,193 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-017895 · ownership.xml · derivative · entry 5 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,193 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The RSUs vested with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares vested on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F6 · derivative.expiration_date: The RSUs vested with respect to 1/8th of the underlying shares on May 16, 2022; thereafter, 1/8th of the underlying shares vested on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:04 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-017895 · ownership.xml · derivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,113 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F5 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:04 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-017895 · ownership.xml · derivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,710 Underlying: Common Stock · 1,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: The RSUs vested with respect to 1/16th of the underlying shares on August 16, 2020. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F4 · derivative.expiration_date: The RSUs vested with respect to 1/16th of the underlying shares on August 16, 2020. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:04 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 18,919 | $37.21 | $703,975.99 |
DisclosureSEC source: 0000950170-24-017895 · ownership.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,908 F3 · shares: Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 44,996 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:04 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 44,996 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-017895 · ownership.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,827 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 121 shares of the Issuer's Common Stock acquired by the Reporting Person on February 15, 2024 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| November 17, 2023 Filed Nov 20, 2023 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 22,685 | $29.10 | $660,058.64 |
DisclosureSEC source: 0001209191-23-056015 · doc4.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,710 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 6, 2022. F4 · price: Represents the weighted average sale price of the shares sold from $28.55 to $29.38 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 17,368 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056015 · doc4.xml · derivative · entry 8 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 225,789 Underlying: Common Stock · 17,368 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F9 · derivative.exercise_date: The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F9 · derivative.expiration_date: The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056015 · doc4.xml · derivative · entry 7 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,572 Underlying: Common Stock · 947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: The RSUs vest with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F8 · derivative.expiration_date: The RSUs vest with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 24,193 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056015 · doc4.xml · derivative · entry 6 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,193 Underlying: Common Stock · 24,193 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F7 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056015 · doc4.xml · derivative · entry 5 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,891 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F6 · derivative.expiration_date: The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056015 · doc4.xml · derivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,420 Underlying: Common Stock · 1,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vest with respect to 1/16th of the underlying shares on August 16, 2020. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F5 · derivative.expiration_date: The RSUs vest with respect to 1/16th of the underlying shares on August 16, 2020. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 22,311 | $28.86 | $643,895.46 |
DisclosureSEC source: 0001209191-23-056015 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,395 F2 · shares: Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 44,996 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 21:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 44,996 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-056015 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| August 17, 2023 Filed Aug 18, 2023 20:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 22,683 | $28.59 | $648,454.80 |
DisclosureSEC source: 0001209191-23-046512 · doc4.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,710 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 6, 2022. F5 · price: Represents the weighted average sale price of the shares sold from $28.07 to $29.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 17,368 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046512 · doc4.xml · derivative · entry 8 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 243,157 Underlying: Common Stock · 17,368 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F10 · derivative.exercise_date: The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F10 · derivative.expiration_date: The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 946 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046512 · doc4.xml · derivative · entry 7 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,519 Underlying: Common Stock · 946 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F9 · derivative.exercise_date: The RSUs vest with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F9 · derivative.expiration_date: The RSUs vest with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 24,193 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046512 · doc4.xml · derivative · entry 6 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,386 Underlying: Common Stock · 24,193 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F8 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046512 · doc4.xml · derivative · entry 5 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,669 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F7 · derivative.expiration_date: The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2021. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 1,709 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046512 · doc4.xml · derivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,130 Underlying: Common Stock · 1,709 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The RSUs vest with respect to 1/16th of the underlying shares on August 16, 2020. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F6 · derivative.expiration_date: The RSUs vest with respect to 1/16th of the underlying shares on August 16, 2020. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 22,311 | $29.80 | $664,867.80 |
DisclosureSEC source: 0001209191-23-046512 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,393 F3 · shares: Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 44,994 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 20:00 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 44,994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-046512 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · balance_after: Includes 302 shares acquired by the Reporting Person on August 15, 2023 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| May 17, 2023 Filed May 18, 2023 20:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 24,424 | $14.01 | $342,168.03 |
DisclosureSEC source: 0001209191-23-030581 · doc4.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,408 F3 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 6, 2022. F4 · price: Represents the weighted average sale price of the shares sold from $13.83 to $14.22 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 17,368 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030581 · doc4.xml · derivative · entry 8 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 260,525 Underlying: Common Stock · 17,368 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F9 · derivative.exercise_date: The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, such that all of the underlying shares shall be vested on February 16, 2027, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F9 · derivative.expiration_date: The RSUs vest with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares shall vest on a quarterly basis, such that all of the underlying shares shall be vested on February 16, 2027, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 947 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030581 · doc4.xml · derivative · entry 7 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,465 Underlying: Common Stock · 947 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: The RSUs vest with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/12th of the remaining underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on November 16, 2025, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F8 · derivative.expiration_date: The RSUs vest with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/12th of the remaining underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on November 16, 2025, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 24,193 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030581 · doc4.xml · derivative · entry 6 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,579 Underlying: Common Stock · 24,193 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F7 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F7 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030581 · doc4.xml · derivative · entry 5 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,447 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F6 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F6 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 1,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-030581 · doc4.xml · derivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,839 Underlying: Common Stock · 1,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F5 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Tax withholdingCommon Stock | 20,572 | $14.09 | $289,859.48 |
DisclosureSEC source: 0001209191-23-030581 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 60,832 F2 · shares: Represents the number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 44,996 shares of Common Stock underlying the Reporting Person's RSUs. Read SEC document |
| May 16, 2023 Filed May 18, 2023 20:02 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionCommon Stock | 44,996 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-030581 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:01 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 64,929 | $14.18 | $920,693.22 |
DisclosureSEC source: 0001209191-23-027626 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,408 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 6, 2022. F2 · price: Represents the weighted average sale price of the shares sold from $13.63 to $14.61 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| April 05, 2023 Filed Apr 7, 2023 20:42 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 55,500 | $15.45 | $857,697.00 |
DisclosureSEC source: 0001209191-23-023808 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,337 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 6, 2022. F2 · price: Represents the weighted average sale price of the shares sold from $15.20 to $15.78 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| March 03, 2023 Filed Mar 4, 2023 01:04 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 62,692 | $10.96 | $687,148.20 |
DisclosureSEC source: 0001209191-23-016060 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,837 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 6, 2022. F2 · price: Represents the weighted average sale price of the shares sold from $10.79 to $11.17 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 01:16 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 2,150 | $13.06 | $28,088.89 |
DisclosureSEC source: 0001209191-23-011450 · doc4.xml · nonDerivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,529 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 6, 2022. F6 · price: Represents the weighted average sale price of the shares sold from $13.04 to $13.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 01:16 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | SaleCommon Stock | 15,567 | $12.65 | $196,977.03 |
DisclosureSEC source: 0001209191-23-011450 · doc4.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,679 F4 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 6, 2022. F5 · price: Represents the weighted average sale price of the shares sold from $12.04 to $13.03 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 01:16 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 946 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011450 · doc4.xml · derivative · entry 8 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,412 Underlying: Common Stock · 946 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F10 · derivative.exercise_date: The RSUs vest with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/12th of the remaining underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on November 16, 2025, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F10 · derivative.expiration_date: The RSUs vest with respect to 25% of the underlying shares on November 16, 2022. Thereafter, 1/12th of the remaining underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on November 16, 2025, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 01:16 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 24,193 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011450 · doc4.xml · derivative · entry 7 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,772 Underlying: Common Stock · 24,193 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F9 · derivative.exercise_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. F9 · derivative.expiration_date: The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 01:16 UTC | BridgeBio Pharma, Inc. BBIO · Entity 3360 | Exercise / conversionRestricted Stock Units · Derivative | 778 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-011450 · doc4.xml · derivative · entry 6 STEPHENSON BRIAN C · CIK 0001780030 · Secretary, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,225 Underlying: Common Stock · 778 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F8 · derivative.exercise_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. F8 · derivative.expiration_date: The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.